US4344968A — Pharmaceutical vehicle

Claim 1

Independent Claim 144 words

A pharmaceutical vehicle comprising (a) a fatty acid glyceride having a melting point higher than 37° C. and being used in an amount of 40 to 80% by weight, (b) (b) one member selected from the group consisting of alamine, glycine, phenylalanine, leucine, isoleucine, valine, lysine, proline, serine, glucose, maltose, mannitol, fructose, galactose, lactose, dextrose, xylitol, sorbitol, mannose, sucrose, dextrin, dextran, xylann, carragheenin, mannan, an alginic acid ester of propyleneglycol, soluble starch, gum arabic, tragacamth gum, α-cyclodextrin, β-cyclodextrin, galactan and inulin: said substances having a particle size smaller than 28 mesh and being used in an amount of 10 to 50% by weight, (c) sodium polyacrylate having a particle size smaller than 28 mesh and being used in an amount of 0.2 to 2% by weight, and (d) a water-soluble surface active agent being used in an amount of 0.05 to 5% by weight.

Claim 2

Dependent Claim 144 words

A pharmaceutical vehicle comprising (a) a fatty acid glyceride having a melting point higher than 37° C. and being used in an amount of 40 to 80% by weight, (b) (b) one member selected from the group consisting of alamine, glycine, phenylalanine, leucine, isoleucine, valine, lysine, proline, serine, glucose, maltose, mannitol, fructose, galactose, lactose, dextrose, xylitol, sorbitol, mannose, sucrose, dextrin, dextran, xylann, carragheenin, mannan, an alginic acid ester of propyleneglycol, soluble starch, gum arabic, tragacamth gum, α-cyclodextrin, β-cyclodextrin, galactan and inulin: said substances having a particle size smaller than 28 mesh and being used in an amount of 10 to 50% by weight, (c) sodium polyacrylate having a particle size smaller than 28 mesh and being used in an amount of 0.2 to 2% by weight, and (d) a water-soluble surface active agent being used in an amount of 0.05 to 5% by weight.

Claim 3

Dependent Claim 33 words

A pharmaceutical vehicle as set forth in claim 1 wherein the fatty acid glyceride is at least one member selected from the group consisting of monoglycerides, diglycerides and triglycerides of vegetable fatty acids.

Claim 4

Dependent Claim 31 words

A pharmaceutical vehicle as set forth in claim 1 wherein the water-soluble surface active agent is at least one member selected from polyoxyethylene sorbitan monooleate and polyoxyethylene sorbitan-hydrogenated castor oil derivatives.

Claim 5

Dependent Claim 159 words

A gradually releasing pharmaceutical composition comprising (a) a fatty acid glyceride having a melting point higher than 37° C. and being used in an amount of 40 to 80% by weight, (b) one member selected from the group consisting of alamine, glycine, phenylalanine, leucine, isoleucine, valine, lysine, proline, serine, glucose, maltose, mannitol, fructose, galactose, lactose, dextrose, xylitol, sorbitol, mannose, sucrose, dextrin, dextran, xylan, carragheenin, mannan, an alginic acid ester of propyleneglycol, soluble starch, gum arabic, tragacamth gum, α-cyclodextrin, β-cyclodextrin, galactan and inulin: said substances having a particle size smaller than 28 mesh, (c) sodium polyacrylate having a particle size smaller than 28 mesh, and being used in an amount of 0.2 to 2% by weight, (d) a water-soluble surface active agent, being used in an amount of 0.05 to 5% by weight, and (e) an effective ingredient being used in an amount of 0.0001 to 50%, based on the total weight of the said (a), (b), (c) and (d).

Claim 6

Dependent Claim 159 words

A gradually releasing pharmaceutical composition comprising (a) a fatty acid glyceride having a melting point higher than 37° C. and being used in an amount of 40 to 80% by weight, (b) one member selected from the group consisting of alamine, glycine, phenylalanine, leucine, isoleucine, valine, lysine, proline, serine, glucose, maltose, mannitol, fructose, galactose, lactose, dextrose, xylitol, sorbitol, mannose, sucrose, dextrin, dextran, xylan, carragheenin, mannan, an alginic acid ester of propyleneglycol, soluble starch, gum arabic, tragacamth gum, α-cyclodextrin, β-cyclodextrin, galactan and inulin: said substances having a particle size smaller than 28 mesh, (c) sodium polyacrylate having a particle size smaller than 28 mesh, and being used in an amount of 0.2 to 2% by weight, (d) a water-soluble surface active agent, being used in an amount of 0.05 to 5% by weight, and (e) an effective ingredient being used in an amount of 0.0001 to 50%, based on the total weight of the said (a), (b), (c) and (d).

Claim 7

Dependent Claim 51 words

A gradually releasing pharmaceutical composition as set forth in claim 4 wherein (a) is a glyceride of a vegetable fatty acid obtained from coconut oil, (b) is glycine, the water-soluble surface active agent (d) is polyoxyethylene sorbitan monooleate and (e) is bleomycins being used in an amount of 0.25 to 3%.

Annuity Stage	Window Opens	Payment Deadline	Surcharge Period Until	Estimated Fee	Status
3.5 Years (Year 4)	1985-08-16	1986-02-15	1986-08-17	$2000.00	Window Closed / Lapsed
7.5 Years (Year 8)	1989-08-16	1990-02-15	1990-08-17	$3760.00	Window Closed / Lapsed
11.5 Years (Year 12)	1993-08-16	1994-02-15	1994-08-17	$7700.00	Window Closed / Lapsed

Pharmaceutical vehicle

Abstract

Inventors

Bibliographic Details

Claims Analysis

References Cited (Backward Citations)

USPTO Annuity & Maintenance Windows

Assigned Categories & Tags

Assign Category Tag